Reduced Serum Somatomedin Activity in Patients with Chronic Liver Disease

1974 ◽  
Vol 47 (4) ◽  
pp. 359-366 ◽  
Author(s):  
A. Wu ◽  
D. B. Grant ◽  
Judy Hambley ◽  
A. J. Levi
Keyword(s):  
Growth Hormone ◽  
Alkaline Phosphatase ◽  
Liver Disease ◽  
Chronic Liver Disease ◽  
Severe Disease ◽  
Chronic Liver ◽  
Hormone Deficiency ◽  
Factor Activity ◽  
Important Site ◽  
Low Serum

1. Somatomedin (SM; sulphation factor) activity was estimated by a chick-cartilage assay in fasting sera from twenty-one patients with chronic liver disease. 2. Low SM values were found in nine out of the ten patients with cirrhosis and in two other patients, one with hepatofibrosis and one with hepatoma. 3. In general, the lowest serum SM activities were found in those patients with the most severe disease and significant correlations were found between serum SM and serum albumin, alkaline phosphatase and bilirubin. 4. Growth hormone was also measured in the samples and concentrations above 10 units/ml were found in seven patients, all of whom had reduced serum SM activities. 5. These findings indicate that low serum SM activity in liver disease is not related to growth hormone deficiency and suggest that the liver may be an important site for SM synthesis in man.

scholarly journals Pruritus is common in patients with chronic liver disease and is improved by nalfurafine hydrochloride

2021 ◽  
Vol 11 (1) ◽  
Author(s):  
Shuhei Yoshikawa ◽  
Takeharu Asano ◽  
Mina Morino ◽  
Keita Matsumoto ◽  
Hitomi Kashima ◽  
...  
Keyword(s):  
Alkaline Phosphatase ◽  
Liver Disease ◽  
Chronic Liver Disease ◽  
Scale Score ◽  
Visual Analog Scale ◽  
Visual Analog Scale Score ◽  
Chronic Liver ◽  
Common Complication ◽  
Analog Scale

AbstractPruritus is known to be a common complication in hepatitis patients, but the exact frequency and degree are not fully elucidated. Thus, we evaluated pruritus of 450 patients with chronic liver disease at our hospital. Pruritus was observed in 240 (53%) of the patients. Pruritus was significantly associated with males (OR = 1.51, P = 0.038) and patients with alkaline phosphatase (ALP) ≥ 200 U/L (OR = 1.56, P = 0.0495) and was significantly less in HBsAg-positive patients (OR = 0.449, P = 0.004). Seasonally, there was no difference in the frequency of pruritus between summer and winter. Of the 24 refractory pruritus patients treated with nalfurafine, 17 (71%) indicated improvement of itch, which is defined as a decrease in the visual analog scale score ≥ 30 mm. Pruritus was improved by nalfurafine both during daytime and nighttime in the Kawashima’s scores evaluation. All patients who received nalfurafine exhibited improved Kawashima’s scores ≥ 1 point during the daytime or nighttime. In conclusion, pruritus occurred in > 50% of patients with chronic liver disease, and predictors of pruritus were males and ALP ≥ 200 U/L. Nalfurafine may be useful for pruritus, regardless of whether daytime or nighttime.

TNF-α and Growth Hormone Resistance in Patients with Chronic Liver Disease

2003 ◽  
Vol 23 (5) ◽  
pp. 229-235 ◽  
Author(s):  
Antonio Picardi ◽  
Umberto Vespasiani Gentilucci ◽  
Enrico Maria Zardi ◽  
Domenico Caccavo ◽  
Tommasangelo Petitti ◽  
...  
Keyword(s):  
Growth Hormone ◽  
Liver Disease ◽  
Chronic Liver Disease ◽  
Chronic Liver ◽  
Hormone Resistance ◽  
Growth Hormone Resistance ◽  
Tnf Α

scholarly journals Chronic Liver Disease and COVID-19: A Perspective From Singapore

2020 ◽  
Author(s):  
Jonathan Kuang ◽  
Huiyu Lin ◽  
Wei Da Chew ◽  
Li Wei Ang ◽  
David Lye ◽  
...  
Keyword(s):  
Liver Cirrhosis ◽  
Liver Disease ◽  
Chronic Liver Disease ◽  
Clinical Course ◽  
Severe Disease ◽  
Chronic Liver ◽  
Alcoholic Fatty Liver ◽  
National Centre ◽  
Prognostic Implications ◽  
Alcoholic Fatty Liver Disease

Abstract Background: Chronic liver diseases including non-alcoholic fatty liver disease (NAFLD) are associated with COVID-19 progression. With no signs of the pandemic abating, thousands worldwide are at risk of a severe disease course. Objective: We aimed to describe the epidemiological features, clinical course, treatment and outcomes of our patients with COVID-19 and chronic liver disease.Methods: A retrospective descriptive study of COVID-19 patients with chronic liver disease admitted to the National Centre for Infectious Diseases in Singapore between 29th February and 2nd May 2020 was performed. Results: 16 patients had chronic liver disease – 9 had NAFLD. In the NAFLD group, peak ALT was higher (median: 84 U/L vs 38 U/L; P = 0.042) and more patients had hyperlipidaemia (88.9% vs 28.6%; p=0.035), but median Body Mass Index (BMI) was not significantly higher (24.3 kg/m2 vs 24.2 kg/m2). NAFLD patients had a poorer clinical course: more required anti-viral medications (66.7% vs 0%; p=0.011), and time to negative swab was longer (24 days vs 13 days; p=0.008). 3 patients had liver cirrhosis (all non-NAFLD). 1 decompensated but none required intensive care unit admission or died.Conclusion: Our results show that in COVID-19 patients with chronic liver disease, those with NAFLD experience a more severe clinical course. In Asians, NAFLD can have poorer prognostic implications, despite them having only mildly raised BMI. We advocate that patients with NAFLD and liver cirrhosis should be closely monitored for COVID-19 disease progression.

Plasma prolidase activity: a possible index of collagen catabolism in chronic liver disease.

1984 ◽  
Vol 30 (2) ◽  
pp. 211-215 ◽  
Author(s):  
I Myara ◽  
A Myara ◽  
M Mangeot ◽  
M Fabre ◽  
C Charpentier ◽  
...  
Keyword(s):  
Alkaline Phosphatase ◽  
Liver Disease ◽  
Chronic Liver Disease ◽  
Total Bilirubin ◽  
Early Stage ◽  
Chronic Liver ◽  
Easy Method ◽  
Prolidase Activity ◽  
Ccl4 Administration ◽  
The Mean

Abstract We describe here an easy method of determining prolidase (EC 3.4.13.9) in plasma after preincubation with Mn2+ for 24 h at 37 degrees C to maximize prolidase activity. The mean activity in 338 patients who were either in hospital or outpatients was 900 U/L +/- 520 (2 SD), unrelated to sex or age. In 25 of these 338 samples tested, prolidase activity was between 1500 and 2000 U/L. It exceeded 2000 U/L in eight, all of whom were patients with chronic liver disease. Plasma prolidase activity was normal in cytolytic syndromes such as liver or heart disease. Of the 27 patients with cirrhosis, only five exhibited prolidase activity greater than 2000 U/L. Plasma prolidase activity was uncorrelated with six biochemical indexes to liver function (the aminotransferases, alkaline phosphatase, glutamyltransferase, total bilirubin, and serum albumin) or with the degree of cirrhotic fibrosis. We believe that plasma prolidase activity may be high only in the early stage of fibrosis. This hypothesis would be consistent with the data on rat-liver collagenolytic activities during CCl4 administration. Monitoring of plasma prolidase activity might be useful in evaluating fibrotic processes in chronic liver disease in the human.

scholarly journals Clinico-biochemical and morphological mapping in chronic liver diseases in patients of the senior age group

2019 ◽  
Vol 11 (3) ◽  
pp. 49-56
Author(s):  
S. V. Stolov ◽  
T. Yu. Yamshchikova ◽  
T. A. Garan ◽  
T. A. Kochergina ◽  
Z. D. Schwazman ◽  
...  
Keyword(s):  
Alkaline Phosphatase ◽  
Liver Cirrhosis ◽  
Chronic Hepatitis ◽  
Liver Disease ◽  
Elderly Patients ◽  
Chronic Liver Disease ◽  
Liver Diseases ◽  
Chronic Liver ◽  
Chronic Liver Diseases ◽  
Histological Activity

Diagnosis of chronic liver diseases in elderly patients has its own features due to polymorbidity, multiple organ failure, being subtle the course of the disease. The purpose of the study was to identify correlations of inflammation biochemical parameters and hepatocellular failure with histology in chronic hepatitis (CH) and liver cirrhosis (LC) in elderly patients. Materials and methods. The study included medical records of patients with chronic liver disease (CLD) who died in the Clinical Hospital for War Veterans of Saint Petersburg between 2009 and 2015 (with the average age of 81 year). The diagnosis of chronic hepatitis (45 cases) and chronic cirrhosis (54 cases) was confirmed by postmortem examination. Morphological changes in the liver were described according to Knodell creteria. The degree of inflammatory activity in the liver was evaluated in points (0.1 to 3.0) depending on the level of AST, ALT, -globulin, alkaline phosphatase, -GTP, bilirubin. For similar scoring severity hepatocellular insufficiency (0.13.0) considered total protein, albumin, prothrombin index, fibrinogen. For cirrhotic patients the Child-Pugh criteria were also used. Results. Chronic liver disease (CLD) hepatitis and cirrhosis of the elderly is detected in 1,5% of cases. In most cases, CLD develop secondary to diseases of the cardiovascular system, and are accompanied by subtle symptoms, which limits their life-time diagnosis. The integral evaluation of the process activity degree according to biochemical indices was significantly higher in the group of chronic hepatitis than in the group of liver cirrhosis. Correlations of the inflammation bichemical parameters (AST and / or ALT, -globulin, alkaline phosphatase, -GTP) having a degree of Knodell Histological Activity Group chronic hepatitis and cirrhosis have not been established. The study established correlation of histological activity with total bilirubin levels in both groups of CLD. Integral assessment of hepatocellular deficiency by biochemical indicators of liver cirrhosis group was higher than in the group of chronic hepatitis.

Resistance to the growth-promoting and metabolic effects of growth hormone in children with chronic liver disease

1990 ◽  
Vol 117 (3) ◽  
pp. 397-402 ◽  
Author(s):  
John C. Bucuvalas ◽  
Wayne Cutfield ◽  
JoAnn Horn ◽  
Mark A. Sperling ◽  
James E. Heubi ◽  
...  
Keyword(s):  
Growth Hormone ◽  
Liver Disease ◽  
Chronic Liver Disease ◽  
Chronic Liver ◽  
Metabolic Effects ◽  
Growth Promoting
Sign in / Sign up

Export Citation Format

Share Document